SAN DIEGO, Jan. 7, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that systematic in vivo testing of the company’s Vaxfectin(R) adjuvant shows that it increased antibody and T-cell responses primarily by stimulating the immune system rather than simply increasing vaccine uptake. The results, published in the journal Vaccine(1), validate encouraging results with the Vaxfectin(R) adjuvant in prior animal and human studies, and position Vaxfectin(R) as a potential “universal” adjuvant for a broad range of vaccines.
